Pathfinder
Editor, Senior Moderator
Secukinumab for plaque psoriasis shows promise in trials
By Rhodi Lee, Tech Times | July 11, 1:14 AM
...
For the two phase III clinical trials of the drug secukinumab, which were sponsored by the drug's producer Novartis Pharmaceuticals and described in an article published in the New England Journal of Medicine on July 9, results showed that the drug holds potential as treatment for people with moderate and severe plaque psoriasis.
"Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target," the researchers concluded.
In one of the trials, investigators randomly gave 738 psoriasis patients 300 milligrams of secukinumab, 150 milligrams of secukinumab, or placebo. Within 12 weeks, four of every five patients who received the higher dose of the injectable drug secukinumab had 75 percent improvement in their symptoms while only one per 20 of the subjects who received placebo did. Fifty-nine percent of the subjects who received 300 mg of the drug also reported 90 percent improvement in their psoriasis symptoms and over 28 percent reported that their psoriasis has completely cleared up.
In another study involving 1,306 psoriasis patients, 77 percent of the patients who received the 300 mg of secukinumab had 75 percent improvement in their symptoms within 12 weeks....
...
"Over a quarter of patients have not a dot of psoriasis left," study author Mark Lebwohl, from the Icahn School of Medicine at Mount Sinai in New York City, told HealthDay.
...
http://www.techtimes.com/articles/1...-plaque-psoriasis-shows-promise-in-trials.htm
-------------------------------------------------------------------------------------------------------------------------------
New England Journal of Medicine
Original Article
Secukinumab in Plaque Psoriasis ? Results of Two Phase 3 Trials
http://www.nejm.org/doi/full/10.1056/NEJMoa1314258#t=articleDiscussion
By Rhodi Lee, Tech Times | July 11, 1:14 AM
...
For the two phase III clinical trials of the drug secukinumab, which were sponsored by the drug's producer Novartis Pharmaceuticals and described in an article published in the New England Journal of Medicine on July 9, results showed that the drug holds potential as treatment for people with moderate and severe plaque psoriasis.
"Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target," the researchers concluded.
In one of the trials, investigators randomly gave 738 psoriasis patients 300 milligrams of secukinumab, 150 milligrams of secukinumab, or placebo. Within 12 weeks, four of every five patients who received the higher dose of the injectable drug secukinumab had 75 percent improvement in their symptoms while only one per 20 of the subjects who received placebo did. Fifty-nine percent of the subjects who received 300 mg of the drug also reported 90 percent improvement in their psoriasis symptoms and over 28 percent reported that their psoriasis has completely cleared up.
In another study involving 1,306 psoriasis patients, 77 percent of the patients who received the 300 mg of secukinumab had 75 percent improvement in their symptoms within 12 weeks....
...
"Over a quarter of patients have not a dot of psoriasis left," study author Mark Lebwohl, from the Icahn School of Medicine at Mount Sinai in New York City, told HealthDay.
...
http://www.techtimes.com/articles/1...-plaque-psoriasis-shows-promise-in-trials.htm
-------------------------------------------------------------------------------------------------------------------------------
New England Journal of Medicine
Original Article
Secukinumab in Plaque Psoriasis ? Results of Two Phase 3 Trials
http://www.nejm.org/doi/full/10.1056/NEJMoa1314258#t=articleDiscussion